title: [First NOAk specific antidote as additional safety factor in therapy].
mesh_terms: D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use*; D000931:Antidotes / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy; D000069604:Dabigatran / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D020521:Stroke / Q000517:prevention & control
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000931:Antidotes; C000594745:idarucizumab; D000069604:Dabigatran